PRKAA1 and glioblastoma: Moreover, in specific glioblastoma and breast cancer cells characterized by hyperactivity of AKT due to loss of PTEN, AMPK is resistant to activation by AMPK activator A769662, though this effect is reversed by addition of MK2206 as an AKT inhibitor [83, 86].